Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- Cholesterol-lowering statins don’t affect ALS progression: Study
- Inflammation may explain why ALS progression is faster for some
- Neurizon gets OK to test liquid form of ALS medication in Australia
- On his birthday, I remember the person who taught me to live fully
- RNA therapy shows promise for addressing key driver of ALS